---
title: "Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/279081167.md"
description: "Acurx Pharmaceuticals (ACXP) has received a Buy rating from Alliance Global Partners, with a price target of $10.00, as reported by James Molloy. Molloy, who covers the Healthcare sector, has an average return of -25.0% and a 19.00% success rate on his recommendations. Additionally, H.C. Wainwright's Matthew Keller also issued a Buy rating for Acurx today, while TipRanks – DeepSeek maintained a Hold rating on the stock."
datetime: "2026-03-13T17:35:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279081167.md)
  - [en](https://longbridge.com/en/news/279081167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279081167.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/279081167.md) | [繁體中文](https://longbridge.com/zh-HK/news/279081167.md)


# Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners

In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Acurx Pharmaceuticals, with a price target of $10.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Molloy covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Tonix Pharma, and Soligenix. According to TipRanks, Molloy has an average return of \-25.0% and a 19.00% success rate on recommended stocks.

In addition to Alliance Global Partners, Acurx Pharmaceuticals also received a Buy from H.C. Wainwright’s Matthew Keller in a report issued today. However, on the same day, TipRanks – DeepSeek reiterated a Hold rating on Acurx Pharmaceuticals (NASDAQ: ACXP).

### 相关股票

- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Acurx Pharmaceuticals (ACXP.US)](https://longbridge.com/zh-CN/quote/ACXP.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)

## 相关资讯与研究

- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/zh-CN/news/279032442.md)
- [Acurx Advances Ibezapolstat Program for Recurrent C. difficile](https://longbridge.com/zh-CN/news/278399773.md)
- [Solid Biosciences: Strengthened Dystrophin Data and Emerging Cardiac Benefits Support Buy Rating on SGT-003](https://longbridge.com/zh-CN/news/278770627.md)
- [Incannex Healthcare Prices $10 Mln Potential Offering Of Shares And Warrants; Stock Down](https://longbridge.com/zh-CN/news/278896600.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-CN/news/278556054.md)